Aldo-keto reductase family 1 member C2, also known as bile acid binding protein, 3α-hydroxysteroid dehydrogenase type 3 (3α-HSD3),[5][6] and dihydrodiol dehydrogenase type 2, is an enzyme that in humans is encoded by the AKR1C2 gene.[7]
Superfamily of enzymes
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols using NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This particular enzyme, AKR1C2, binds bile acid with high affinity, and shows minimal 3α-hydroxysteroid dehydrogenase activity. The AKR1C2 gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. Three transcript variants encoding two different isoforms have been found for this gene.[7] The AKR1C2 enzyme catalyzes reactions at specific positions on the steroid nucleus. Specifically, AKR enzymes, including AKR1C2, act as 3α/β-HSDs, 17β-HSDs, and 20α-HSDs, catalyzing NAD(P)(H)-dependent oxidoreduction of substituents at the C3, C17, and C20 positions of the steroid nucleus.[8][9][10]
Aldo-keto reductase activity
AKR1C2 binds bile acid with high affinity catalyzing aldo-keto reduction reaction.[7]
Aldo-keto reductases, including AKR1C2, are NAD(P)H-linked oxidoreductases that primarily catalyze the reduction of aldehydes and ketones to primary and secondary alcohols. This reduction is dependent on NADPH.[11][12]
In the context of bile acids, the AKR1C2 enzyme would bind to the bile acid (a type of steroid molecule) and catalyze the reduction of a carbonyl group (C=O) present in the bile acid to a hydroxy group (-OH), using NADPH as a cofactor.[11][12] This reaction is part of the broader metabolic processes that these enzymes are involved in, which include biosynthesis, intermediary metabolism, and detoxification.[11][12]
3α-hydroxysteroid dehydrogenase activity
The AKR1C2 enzyme is also known as 3α-hydroxysteroid dehydrogenase type 3 (3α-HSD3), meaning that the enzyme possesses 3α-hydroxysteroid dehydrogenase activity, i.e. it can hydroxylate steroids at a carbon position 3α of the steroid nucleus, attaching the hydroxy group (-OH) to carbon 3 in α stereiodirection. 3α-hydroxysteroid dehydrogenases, including AKR1C2, are NAD(P)H-linked oxidoreductases that primarily catalyze the oxidation of 3α-hydroxysteroids to their corresponding 3-ketosteroids. This oxidation is dependent on NAD+. The substrates for the 3α-HSD3 enzyme are steroids such as androgens, estrogens, and progestins, which regulate various sex functions. For example, 3α-HSD3 can catalyze the conversion of the potent androgen 5α-dihydrotestosterone (DHT) into its much less active form, 5α-androstan-3α,17β-diol (3α-diol), effectively deactivating biological action of DHT.[13][14][15][16]
Isozymes of aldo-keto reductase family 1 member C
| HGNC Gene Symbol | Enzyme Name Aliases[17] |
|---|---|
| AKR1C1 | aldo-keto reductase family 1 member C1; 20α-hydroxysteroid dehydrogenase |
| AKR1C2 | aldo-keto reductase family 1 member C2; 3α-hydroxysteroid dehydrogenase type 3 |
| AKR1C3 | aldo-keto reductase family 1 member C3; 3α-hydroxysteroid dehydrogenase type 2; 17β-hydroxysteroid dehydrogenase type 5; HSD17B5 |
| AKR1C4 | aldo-keto reductase family 1 member C4; 3α-hydroxysteroid dehydrogenase type 1 |
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000151632 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000021207 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Zhang B, Zhu DW, Hu XJ, Zhou M, Shang P, Lin SX (2014). "Human 3-alpha hydroxysteroid dehydrogenase type 3 (3α-HSD3): The V54L mutation restricting the steroid alternative binding and enhancing the 20α-HSD activity". The Journal of Steroid Biochemistry and Molecular Biology. 141: 135–143. doi:10.1016/j.jsbmb.2014.01.003. PMID 24434280.
- ^ Li T, Zhang W, Lin SX (2020). "Steroid enzyme and receptor expression and regulations in breast tumor samples – A statistical evaluation of public data". The Journal of Steroid Biochemistry and Molecular Biology. 196. doi:10.1016/j.jsbmb.2019.105494. PMID 31610224. Archived from the original on 2024-04-17. Retrieved 2024-04-08.
- ^ a b c "Entrez Gene: AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)". National Center for Biotechnology Information, U.S. National Library of Medicine. Archived from the original on 2019-03-29.
This article incorporates text from this source, which is in the public domain.
- ^ Feder HH (1981). "Essentials of Steroid Structure, Nomenclature, Reactions, Biosynthesis, and Measurements". Neuroendocrinology of Reproduction. pp. 19–63. doi:10.1007/978-1-4684-3875-8_3. ISBN 978-1-4684-3875-8.
- ^ Penning TM, Wangtrakuldee P, Auchus RJ (20 August 2018). "Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes". Endocrine Reviews. 40 (2): 447–475. doi:10.1210/er.2018-00089. PMC 6405412. PMID 30137266.
- ^ Zhou Y, Lin Y, Li W, Liu Q, Gong H, Li Y, Luo D (February 2023). "Expression of AKRs superfamily and prognostic in human gastric cancer". Medicine (Baltimore). 102 (8): e33041. doi:10.1097/MD.0000000000033041. PMID 36827074.
- ^ a b c Zeng CM, Chang LL, Ying MD, Cao J, He QJ, Zhu H, Yang B (14 March 2017). "Aldo-Keto Reductase AKR1C1-AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy". Front Pharmacol. 8: 119. doi:10.3389/fphar.2017.00119. PMC 5349110. PMID 28352233.
- ^ a b c Chen WD, Zhang Y (9 March 2012). "Regulation of aldo-keto reductases in human diseases". Front Pharmacol. 3: 35. doi:10.3389/fphar.2012.00035. PMC 3297832. PMID 22408622.
- ^ Rižner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM (1 July 2003). "Human Type 3 3α-Hydroxysteroid Dehydrogenase (Aldo-Keto Reductase 1C2) and Androgen Metabolism in Prostate Cells". Endocrinology. 144 (7): 2922–2932. doi:10.1210/en.2002-0032. PMID 12810547.
- ^ Lewis MJ, Wiebe JP, Heathcote JG (2004). "Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma". BMC Cancer. 4: 27. doi:10.1186/1471-2407-4-27. PMC 459223. PMID 15212687.
- ^ "Human type 3 3alpha-hydroxysteroid dehydrogenase (Aldo-keto reductase 1C2) and androgen metabolism in prostate cells. | DrugBank Online". Archived from the original on 2024-04-17. Retrieved 2024-04-17.
- ^ Dufort I, Labrie F, Luu-The V (1 February 2001). "Human Types 1 and 3 3α-Hydroxysteroid Dehydrogenases: Differential Lability and Tissue Distribution1". The Journal of Clinical Endocrinology & Metabolism. 86 (2): 841–846. doi:10.1210/jcem.86.2.7216. PMID 11158055.
- ^ Dufort I, Labrie F, Luu-The V (February 2001). "Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution". J Clin Endocrinol Metab. 86 (2): 841–6. doi:10.1210/jcem.86.2.7216. PMID 11158055.
human types 1 and 3 3α-HSD, 20α-HSD, and type 5 17β-HSD were named AKR1C4, AKR1C2, AKR1C1, and AKR1C3, respectively
External links
- Human AKR1C2 genome location and AKR1C2 gene details page in the UCSC Genome Browser.
 | This article on a gene on human chromosome 10 is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 12 May 2024, at 15:19